Compare InMode Ltd (INMD) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Inovio Pharmaceuticals Inc — how do they compare? InMode Ltd trades at $15.33 (market cap $882.90M), while Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M). The key difference: InMode Ltd is far larger — about 9.9× Inovio Pharmaceuticals Inc's market cap, and InMode Ltd is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INMD | INO | |
|---|---|---|
Market Cap | $882.90M | $89.27M |
Sector | Technology | Health |
52-Week High | $16.62 | $2.87 |
52-Week Low | $12.76 | $1.05 |
Enterprise Value | $350.57M | $60.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and upcoming Q2 2026 results on August 5, 2026.
The stock presents a mixed outlook: attractive valuation multiples and a solid balance sheet support upside, but risks include earnings volatility, shareholder activism, and a securities fraud investigation. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism near-term.
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
